<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Malignant salivary gland tumors: Treatment of recurrent and metastatic disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Malignant salivary gland tumors: Treatment of recurrent and metastatic disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Malignant salivary gland tumors: Treatment of recurrent and metastatic disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott A Laurie, MD, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley Schiff, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall R Posner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Brizel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marvin P Fried, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Salivary glands produce and secrete saliva from a glandular structure that includes the secretory acinus, the ducts, and the myoepithelial and basal cells. Salivary gland tumors can be benign or malignant  (<a class="graphic graphic_table graphicRef116708" href="/d/graphic/116708.html" rel="external">table 1</a>) and can arise from either the major (parotid, submandibular, and sublingual) or minor salivary glands located in the oral cavity, paranasal sinuses, larynx, and pharynx  (<a class="graphic graphic_figure graphicRef115303" href="/d/graphic/115303.html" rel="external">figure 1</a>).</p><p>The most common malignant salivary gland tumors include adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma, secretory carcinomas, acinic cell carcinoma, and various adenocarcinoma histologies, including salivary ductal carcinoma.</p><p>Salivary gland tumors are rare, and information on management of locoregional and metastatic disease is based on retrospective series and phase II trials, most commonly in ACC. These data and the approach to treatment of locoregionally recurrent and metastatic salivary gland tumors are reviewed here.</p><p>The initial treatment of locoregional disease and the epidemiology, risk factors, pathology, and clinical features of these tumors are discussed separately. (See  <a class="medical medical_review" href="/d/html/3377.html" rel="external">"Salivary gland tumors: Treatment of locoregional disease"</a> and  <a class="medical medical_review" href="/d/html/3400.html" rel="external">"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging"</a>.)</p><p class="headingAnchor" id="H2332326542"><span class="h1">LOCOREGIONALLY RECURRENT DISEASE</span><span class="headingEndMark"> — </span>Treatment options for recurrent salivary gland tumors, as with recurrent head and neck cancer in general, are limited by the previous therapy received and the potential resectability of recurrent disease. (See  <a class="medical medical_review" href="/d/html/3373.html" rel="external">"Treatment of locally recurrent squamous cell carcinoma of the head and neck"</a>.)</p><p>Treatment of recurrent pleomorphic adenoma (benign mixed tumor) is discussed separately. (See  <a class="medical medical_review" href="/d/html/3377.html" rel="external">"Salivary gland tumors: Treatment of locoregional disease", section on 'Pleomorphic adenoma'</a>.)</p><p class="headingAnchor" id="H3850420496"><span class="h2">Local relapse</span><span class="headingEndMark"> — </span>In general, surgical salvage is the optimal treatment for resectable recurrent salivary gland tumors, although outcomes with surgical salvage are disappointing [<a href="#rid1">1,2</a>].</p><p>If at all possible, attempts should be made for complete surgical resection since that provides the best chance for locoregional disease control and, potentially, cure. Depending on the location of the recurrence, surgery can be associated with significant morbidity and may involve sacrifice of the skin, facial nerve, or deeper structures of the face and neck. However, these potentially morbid surgeries should be considered in patients without distant metastatic disease as surgery in these patients can be potentially curative.</p><p>Even if distant metastatic disease is present, resection of local recurrence may reduce morbidity compared with alternatives, particularly if the patient has already been treated with radiation therapy (RT). For patients who have not received RT as part of treatment for their original disease presentation and who subsequently develop an isolated local recurrence, we suggest adjuvant RT following salvage surgery, as these patients are at high risk for future relapses. If RT has previously been received, reirradiation should be decided on a case-by-case basis in a multidisciplinary setting.</p><p>Irradiation or, in some cases, reirradiation is an option for nonsurgical treatment of locally recurrent salivary gland tumors. If reirradiation is being considered, patient selection is critical due to its toxicity and the likelihood of resistant disease, especially with tumor recurrence within six months after the first course of treatment. (See  <a class="medical medical_review" href="/d/html/3384.html" rel="external">"Reirradiation for locally recurrent head and neck cancer"</a>.)</p><p>RT for recurrent disease is generally carried out with conventional external beam RT using photons. Alternative approaches include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>High linear energy transfer RT (eg, protons, neutrons, carbon ions) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/3377.html" rel="external">"Salivary gland tumors: Treatment of locoregional disease", section on 'Definitive treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraoperative RT (combined with salvage surgery) and brachytherapy offer additional options for salvage therapy but are usually reserved for patients who previously received external beam RT [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/3384.html" rel="external">"Reirradiation for locally recurrent head and neck cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RT combined with local hyperthermia or concurrent chemoradiotherapy may play a role in the treatment of some locally advanced or recurrent salivary gland tumors, but experience is limited, and these remain investigational approaches [<a href="#rid5">5-8</a>].</p><p></p><p>If neither surgery nor RT is feasible, then systemic therapy may be appropriate. (See <a class="local">'Metastatic disease'</a> below.)</p><p class="headingAnchor" id="H2922518424"><span class="h2">Regional recurrence</span><span class="headingEndMark"> — </span>Neck dissection, with or without postoperative RT, is performed, if feasible, for surgical salvage of regional lymph node recurrence. If the patient has not yet received RT to the neck, postoperative RT may also be used for high-grade tumors, multiple nodes, close margins, or extracapsular lymph node spread. Regional recurrence with adenoid cystic carcinoma (ACC) is a particular problem since the perineural tumor spread is usually intracranial and surgical resection at the skull base is particularly morbid.</p><p class="headingAnchor" id="H2"><span class="h1">METASTATIC DISEASE</span><span class="headingEndMark"> — </span>The most common sites of distant metastatic involvement with malignant salivary gland tumors are the lung, liver, and bone.</p><p class="headingAnchor" id="H922917116"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>The natural history of metastatic disease is variable, and some patients remain asymptomatic for protracted periods of time. This is especially true for adenoid cystic carcinomas (ACCs; particularly when metastases are limited to the lung), acinic cell carcinomas, and myoepithelial carcinomas [<a href="#rid9">9-16</a>]. Although there is a wide spectrum of biologic behavior [<a href="#rid17">17</a>], median survival following the development of metastatic ACC was approximately three years in older series, which is substantially longer than expected for most other solid tumors [<a href="#rid10">10-12</a>]. This is especially true for patients with ACC identified with asymptomatic disease who are diagnosed using screening computed tomography (CT) [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1807579783"><span class="h2">Indications for treatment</span></p><p class="headingAnchor" id="H1682469134"><span class="h3">Local treatments</span><span class="headingEndMark"> — </span>Patients may have one single site affecting a critical structure (eg, bronchial obstruction from a lung metastasis, pain or fracture from a bony metastasis) but have otherwise stable systemic disease. For these patients, we offer locoregional therapies such as surgery, radiofrequency ablation, or radiation therapy (RT) to the symptomatic site.</p><p>Additionally, long-term survival has been reported with definitive local therapy for those with oligometastatic salivary gland tumors, specifically for those with solitary pulmonary or hepatic metastases, with most data in those with ACC histology [<a href="#rid14">14,18-24</a>]. Most of these patients are treated with metastasectomy. However, radiofrequency ablation and RT (including stereotactic body irradiation and brachytherapy) may be of some benefit in ACC and can be alternatives to surgical intervention in select patients.</p><p>As an example, in a series of 83 patients with metastatic head and neck cancer who underwent resection of pulmonary metastases, patients with metastatic ACC had a five-year survival of 84 percent [<a href="#rid23">23</a>]. However, overall survival (OS) continued to decline until there were no survivors after 14 years. It is unclear if this reflects the indolent nature of this disease or a true benefit of metastasectomy.</p><p>Once locoregional therapy is completed with improvement of symptoms, some patients may be observed, while others may benefit from systemic therapy. Indications are discussed below. (See <a class="local">'Systemic treatment'</a> below.)</p><p class="headingAnchor" id="H2797245274"><span class="h3">Systemic treatment</span><span class="headingEndMark"> — </span>Systemic therapy, either with chemotherapy or targeted agents, is offered to patients with an increasing rate of systemic disease progression based on imaging studies, with systemic symptoms, with threatened end-organ dysfunction, and/or with a declining performance status due to progressive disease. Systemic therapy can be administered irrespective of whether local treatments have also been administered, but it may be particularly useful when local treatments are not feasible. (See <a class="local">'Local treatments'</a> above.)</p><p class="headingAnchor" id="H672617053"><span class="h3">Surveillance for those without treatment indications</span><span class="headingEndMark"> — </span>For most patients with stable disease or slow disease progression that is minimally symptomatic, we observe until there is clinical evidence of rapid and/or symptomatic disease progression.</p><p>There is no standard approach to observation. We offer clinical surveillance with physical examination, laboratory evaluation (including alkaline phosphatase for those with bone metastases and full liver function testing for those with liver metastases), and imaging using a chest radiograph or CT of the chest every three to six months. For tumors with perineural spread noted on pathology, we offer magnetic resonance imaging (MRI) of the head and neck regions. There are no data to support the use of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for surveillance.</p><p class="headingAnchor" id="H2677986620"><span class="h2">Approach to systemic therapy</span><span class="headingEndMark"> — </span>Treatment choice is based on the rate of disease progression and symptoms, histology and presence of clinically actionable molecular targets, and patient preferences, performance status, and comorbidities  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>). </p><p>Chemotherapy is one option for systemic therapy. Whether chemotherapy alters the natural history of most metastatic salivary gland tumor histologies, especially ACC, is unclear [<a href="#rid25">25</a>].</p><p>Treatments can also be personalized based on actionable molecular targets [<a href="#rid25">25-27</a>]. Therefore, we assess for targetable mutations in patients with recurrent or metastatic salivary gland tumors. Molecular characterization of rare salivary gland tumors is rapidly advancing. Actionable targets include neurotrophic tropomyosin receptor kinase (<em>NTRK</em>), human epidermal growth factor receptor 2 (HER2), androgen receptor, rearranged during transfection (<em>RET</em>) gene fusions, and <em>BRAF</em> V600E mutations. Some of these molecular alterations are identifiable in specific histologies of salivary gland tumors, and most targeted therapies result in high response rates [<a href="#rid26">26</a>]. (See <a class="local">'Molecular testing'</a> below and <a class="local">'RET fusion-positive tumors'</a> below.)</p><p>The goals of treatment are generally palliative since there is no evidence that systemic therapy prolongs survival in metastatic salivary gland tumors, with few exceptions. Palliative and supportive care should be integrated with therapy, similar to other advanced head and neck cancers. (See  <a class="medical medical_review" href="/d/html/83242.html" rel="external">"Palliative care: Overview of cough, stridor, and hemoptysis in adults"</a> and  <a class="medical medical_review" href="/d/html/85949.html" rel="external">"Swallowing disorders and aspiration in palliative care: Definition, pathophysiology, etiology, and consequences", section on 'Head and neck cancer'</a>.)</p><p>Clinical trial enrollment is encouraged, where available. However, there are few adequate clinical trials to define the optimal approach to patients with metastatic salivary gland tumors because of the rarity of these tumors.</p><p class="headingAnchor" id="H1042641584"><span class="h2">Salivary gland tumors of any histology with rare driver mutations</span></p><p class="headingAnchor" id="H202916455"><span class="h3">RET fusion-positive tumors</span><span class="headingEndMark"> — </span>For most patients with a metastatic salivary gland tumor of any histology harboring a rearranged during transfection (<em>RET)</em> gene fusion and no other actionable mutations, we suggest initial therapy with <a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">selpercatinib</a> rather than chemotherapy or other systemic agents. Although data are limited to treatment-refractory disease, selpercatinib offers the opportunity for a prolonged treatment response, is well tolerated, and can be administered orally for patient convenience [<a href="#rid28">28</a>]. In contrast, the optimal chemotherapy regimen is not established for most salivary gland tumors (including ACC). Chemotherapy also has modest activity with limited durable responses and significant risk of toxicity. (See <a class="local">'Choice of chemotherapy'</a> below.)</p><p><a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">Selpercatinib</a> is also an option for patients with <em>RET</em> fusion-positive tumors who have progressed on chemotherapy or other systemic agents and have not previously received this targeted agent.</p><p><em>RET</em> gene fusions have been seen in solid malignancies such as lung, thyroid, and gastrointestinal cancers, but are rarely observed in salivary gland cancers. <a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">Selpercatinib</a>, a selective RET kinase inhibitor, was evaluated in an open-label phase I/II basket trial (LIBRETTO-001) of 41 patients with <em>RET </em>fusion-positive tumor agnostic cancers who had progressed on prior systemic therapies [<a href="#rid28">28</a>]. Within the subgroup of four patients with salivary gland tumors, objective responses were seen in two patients (50 percent) and median duration of response was not reached. Grade ≥3 toxicities included hypertension (22 percent) and increased serum transaminases (13 to 16 percent). However, the true clinical benefit of selpercatinib in salivary gland tumors is unclear due to the limited number of patients and further data are necessary.</p><p>Based on these data, the FDA granted accelerated approval to <a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">selpercatinib</a> for adult patients with locally advanced or metastatic solid tumors with <em>RET</em> gene fusion that have progressed on or following prior systemic treatment <strong>or</strong> who have no satisfactory alternative treatment options [<a href="#rid29">29</a>]. </p><p class="headingAnchor" id="H609175838"><span class="h3">BRAF V600E mutant tumors</span><span class="headingEndMark"> — </span>For patients with a metastatic salivary gland tumor of any histology that harbors a <em>BRAF</em> V600E mutation and no other actionable molecular alterations, we suggest initial therapy with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> rather than chemotherapy or other systemic agents. </p><p><a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">Dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> has accelerated approval from the United States Food and Drug Administration for patients with any unresectable or metastatic solid tumor with a <em>BRAF</em> V600E mutation who have progressed on prior therapy and have no satisfactory alternative treatment options [<a href="#rid30">30,31</a>]. However, we prefer to offer the combination as initial therapy for the rare patient with a metastatic <em>BRAF</em> V600E mutant salivary gland tumor. In case reports, dabrafenib plus trametinib has demonstrated robust, prolonged disease response in metastatic salivary gland tumors [<a href="#rid32">32</a>]. The combination is well tolerated in most patients and can be administered orally for patient convenience. In contrast, the optimal chemotherapy regimen is not established for most salivary gland tumors (including ACC). Chemotherapy also has modest activity with limited durable responses and significant risk of toxicity. (See <a class="local">'Choice of chemotherapy'</a> below.)</p><p class="headingAnchor" id="H903109430"><span class="h2">Adenoid cystic carcinoma</span></p><p class="headingAnchor" id="H3478317569"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic ACC who have stable or indolent, minimally symptomatic disease, we offer either surveillance or local therapies such as surgery, ablative therapies, or RT. (See <a class="local">'Surveillance for those without treatment indications'</a> above and <a class="local">'Local treatments'</a> above.)</p><p>Treatment for <em>RET</em> fusion-positive tumors or <em>BRAF</em> V600E mutant tumors of any histology (including ACC) is discussed separately. (See <a class="local">'RET fusion-positive tumors'</a> above and <a class="local">'BRAF V600E mutant tumors'</a> above.)</p><p>In our clinical experience, for patients with advanced or metastatic ACC who lack a targetable mutation and meet the clinical indications for systemic therapy, we offer chemotherapy as initial treatment  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>). Unlike other histologies, however, we avoid <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> in those with ACC, due to lack of efficacy. (See <a class="local">'Systemic treatment'</a> above and <a class="local">'Choice of chemotherapy'</a> below.)</p><p class="headingAnchor" id="H3958958113"><span class="h3">Subsequent therapy</span><span class="headingEndMark"> — </span>Upon disease progression, for patients with ACC that lack a targetable mutation, we offer subsequent-line treatment with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs), such as <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, or evaluation for clinical trials. None of these agents is approved for this indication by the US Food and Drug Administration (FDA), and their use is considered off label. We prefer an initial dose reduction of lenvatinib, starting between 10 and 20 mg daily, with uptitration to the standard dose of 24 mg daily as tolerated. In our experience and in clinical trials, initiating lenvatinib at higher doses increased toxicities [<a href="#rid33">33,34</a>].</p><p>In a single-arm, open-label phase II trial, 33 patients with ACC and confirmed disease progression received <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> 24 mg orally daily [<a href="#rid33">33</a>]. Patients received prior therapy for recurrent/metastatic disease, including targeted agents (other than lenvatinib), chemotherapy, immunotherapy, or RT. Approximately one-third of the patients in this study had received prior palliative chemotherapy, with or without RT; two-thirds had received adjuvant chemotherapy, with or without RT; and approximately one-third had received targeted therapy, including six patients with VEGF TKIs. After a median follow-up of 5.2 months, lenvatinib demonstrated a partial response rate of 16 percent, a stable disease rate of 75 percent, and median progression-free survival (PFS) of 17.5 months. Grade ≥3 toxicities included hypertension, oral pain, myocardial infarction, posterior reversible encephalopathy syndrome, and intracranial hemorrhage. Approximately two-thirds of the patients required a dose reduction of lenvatinib to between 10 and 20 mg, and approximately one-half discontinued therapy due to treatment-related toxicities.</p><p>Although other VEGF inhibitors, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> and <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, may be acceptable alternatives to <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> for ACC, we prefer lenvatinib because trials of other agents did not require progression as an eligibility criterion, which raises questions regarding the observed rates of clinical benefit. In patients with ACC, sorafenib and axitinib have demonstrated clinical response rates of 16 and 9 percent, respectively [<a href="#rid35">35-37</a>].</p><p class="headingAnchor" id="H2339724815"><span class="h2">Nonadenoid cystic carcinoma</span></p><p class="headingAnchor" id="H1346894511"><span class="h3">Molecular testing</span><span class="headingEndMark"> — </span>For patients with nonadenoid cystic tumors eligible for systemic therapy, the choice of chemotherapy versus targeted agents is influenced by the presence of specific genomic alterations. For most salivary gland tumors, the initial choice of molecular testing is determined based on histology. In general, actionable molecular alterations are rare in salivary gland tumors, aside from the following  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>):</p><p>For patients with <strong>secretory tumors</strong> (eg, mammary analog secretory carcinoma [MASC]), we offer assessment for a neurotrophic tyrosine receptor kinase (<em>NTRK</em>) gene fusion. The diagnostic approach to detecting <em>NTRK</em> gene fusions (including other available assays) is discussed separately  (<a class="graphic graphic_algorithm graphicRef126093" href="/d/graphic/126093.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In those with tumors that test positive for an <em>NTRK</em> gene fusion, we offer first-line therapy with <a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a> rather than chemotherapy. (See <a class="local">'Secretory (NTRK gene fusion positive)'</a> below.)</p><p></p><p class="bulletIndent1">For patients with <strong>nonsecretory</strong> tumor histology (eg, mucoepidermoid tumors, salivary ductal carcinomas [SDC], adenocarcinomas not otherwise specified [NOS]), we test for both HER2 and androgen receptor status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HER2 expression status is assessed using immunohistochemistry (IHC), with reflex to fluorescent in situ hybridization (FISH) as clinically indicated. If positive (ie, IHC 3+, <strong>or</strong> IHC 2+ plus FISH HER2/chromosome 17 [CEP17] ratio ≥2), we offer trastuzumab-based therapy. (See <a class="local">'HER2 overexpression'</a> below.)</p><p></p><p class="bulletIndent1">This is analogous to HER2 testing in breast cancer. (See  <a class="medical medical_review" href="/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer", section on 'Testing for HER2 expression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Androgen receptor status is assessed based on IHC. If positive, we offer chemotherapy as initial therapy and androgen receptor blockade as later-line therapy. (See <a class="local">'Androgen receptor positive'</a> below and <a class="local">'Choice of chemotherapy'</a> below.)</p><p></p><p class="headingAnchor" id="H2894452708"><span class="h3">Secretory (NTRK gene fusion positive)</span><span class="headingEndMark"> — </span>For patients with secretory carcinomas of the salivary glands, also known as MASC, whose tumors test positive for a neurotrophic tyrosine receptor kinase (<em>NTRK</em>) gene fusion, we offer first-line therapy with <a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a> rather than chemotherapy  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>). (See <a class="local">'Molecular testing'</a> above.)</p><p>MASC is histologically and genetically similar to secretory carcinomas of the breast. Activating gene fusions of the <em>NTRK3</em> gene are found in virtually all cases of MASC but not in other subtypes of salivary gland tumors. While various <em>NTRK</em> gene fusions have been identified, the most commonly detected gene in MASC is <em>ETV6-NTRK3</em>, which occurs from the balanced chromosomal translocation t(12;15) [<a href="#rid26">26,38-40</a>]. (See  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Diagnosis'</a>.)</p><p><a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">Larotrectinib</a> and <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a> are oral selective inhibitors of <em>NTRK</em> that have demonstrated high response rates in MASC of the salivary gland [<a href="#rid41">41-44</a>]. Both agents are approved by the FDA for solid tumors (including MASC) with an <em>NTRK</em> gene fusion, without a known acquired resistance mutation, that are either metastatic or unresectable with no satisfactory alternative treatments, or that have progressed following treatment. We prefer larotrectinib over entrectinib as initial treatment in <em>NTRK</em>-positive MASC. Larotrectinib has been used to treat more patients with MASC, has had longer follow-up with more durable responses, and has a better toxicity profile compared with entrectinib, which has been associated with cardiac toxicity and skeletal fractures [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Other toxicities specific to entrectinib'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Larotrectinib</strong><strong> </strong>– In a combined analysis of three phase I to II studies, 159 patients with various malignancies receiving previous chemotherapy were treated with <a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">larotrectinib</a> [<a href="#rid41">41,44</a>]. Among the 21 patients with MASC of the salivary glands, objective responses were seen in 18 patients (90 percent); the median duration of response was 35 months [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entrectinib</strong> – In a pooled analysis of three single-arm trials (ALKA, STARTRK-1, and STARTRK-2), the objective response rate to <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a> among 54 patients with relapsed, advanced or metastatic, <em>NTRK</em>-positive solid tumors was 57 percent [<a href="#rid43">43</a>]. Among the seven patients with salivary gland tumors (all MASC histologies), the overall response rate was 86 percent, and duration of response ranged between 3 and 17 months [<a href="#rid45">45</a>].</p><p></p><p>Further data on the efficacy and toxicity of <a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">larotrectinib</a> and <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a> in other tumor histologies are discussed separately. (See  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Treatment with TRK inhibitors'</a>.)</p><p class="headingAnchor" id="H3226161275"><span class="h3">Nonsecretory</span></p><p class="headingAnchor" id="H1595901161"><span class="h4">HER2 overexpression</span><span class="headingEndMark"> — </span>Up to 30 percent of mucoepidermoid carcinomas and up to 40 percent of SDC overexpress human epidermal growth factor receptor 2 (HER2) or have <em>ERRB2</em> (the HER2 proto-oncogene) amplification as detected by FISH [<a href="#rid46">46</a>]. In contrast, expression of HER2 is unusual in ACCs [<a href="#rid47">47-52</a>].</p><p class="headingAnchor" id="H584962310"><span class="h5">Initial therapy</span><span class="headingEndMark"> — </span>In salivary gland tumors with non-ACC histology and HER2 overexpression, we suggest the addition of taxane-based chemotherapy to <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> as initial therapy  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>). Options include either a single-agent taxane (eg, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> or <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>) or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus paclitaxel with trastuzumab. For patients who wish to avoid the potential toxicities of chemotherapy or those with a contraindication to taxanes, trastuzumab plus <a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">pertuzumab</a> is an appropriate alternative. We typically do not offer single-agent trastuzumab due to limited data.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Taxanes plus </strong><strong>trastuzumab</strong> – <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a>, alone and in combination with chemotherapy is effective in patients with HER2 overexpression for both SDC and mucoepidermoid carcinoma, with some patients demonstrating long-term durable responses [<a href="#rid51">51,53-60</a>].</p><p></p><p class="bulletIndent1">As an example, in an open-label phase II trial of 57 patients with HER2-positive SDC, at a median follow-up of 28 months, <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> demonstrated an overall response rate of 70 percent, with median PFS and OS of approximately 9 and 40 months, respectively [<a href="#rid55">55</a>]. Grade ≥3 toxicities included febrile neutropenia and anemia. Similarly, a phase II trial in patients with HER2-positive SDC using docetaxel-PM (an investigational micellar formulation of docetaxel) and trastuzumab-pkrb (a trastuzumab biosimilar) also suggested a response rate of 70 percent [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">We typically do not offer single-agent <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, as there are limited data for this approach. In one observational study, among three patients with mucoepidermoid carcinoma, one had a partial response to trastuzumab lasting longer than two years, while two patients with previously progressive SDC had disease stabilization for 26 and 40 weeks, respectively [<a href="#rid48">48,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trastuzumab</strong><strong> plus </strong><strong>pertuzumab</strong> – The combination of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">pertuzumab</a> is an option for patients with HER2-positive salivary gland tumors who wish to avoid the potential toxicities of chemotherapy or those with a contraindication to taxanes. In a phase II basket trial, a subgroup of 15 patients with HER2-positive salivary gland tumors (SDCs and mucoepidermoid carcinoma) and no prior exposure to HER2 targeted therapy were treated with trastuzumab plus pertuzumab. Objective responses were seen in nine patients (60 percent) [<a href="#rid62">62</a>]. Median PFS and OS were 9 and 21 months, respectively. Toxicities were consistent with the known safety profiles of these agents.</p><p></p><p class="headingAnchor" id="H3221465441"><span class="h5">Subsequent therapy</span><span class="headingEndMark"> — </span>For patients who progress on trastuzumab-based therapy, options include <a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a> (T-DM1) [<a href="#rid47">47-59</a>] and <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ado-trastuzumab emtansine</strong> – T-DM1 is an appropriate subsequent-line option after progression on trastuzumab-based therapy [<a href="#rid53">53,63</a>]. In a phase II trial of 10 HER2-overexpressing salivary gland tumors of varying histology previously treated with HER2-targeted or endocrine therapy, T-DM1 demonstrated an overall response rate of 90 percent, including five patients (50 percent) with complete clinical responses [<a href="#rid53">53</a>]. After a median follow-up of 12 months, median duration of response and PFS were not reached. Treatment was well tolerated, with grade 1 to 2 infusion reactions, transaminitis, anemia, and rash, and grade ≥3 thrombocytopenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fam-trastuzumab deruxtecan</strong> – <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> is also an option after progression on <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>. This agent was evaluated in a subgroup analysis of two phase I trials that included 17 patients with HER2-positive salivary duct carcinoma; a majority (14 patients) had previously received HER2 targeted therapy, including trastuzumab [<a href="#rid64">64</a>]. Objective responses were seen in 8 patients (47 percent). Median duration of response and PFS were 13 and 14 months, respectively. The grade 3 toxicity rate was 65 percent and were mostly hematologic toxicities.</p><p></p><p class="headingAnchor" id="H3551776757"><span class="h4">Androgen receptor positive</span><span class="headingEndMark"> — </span>Hormone receptor expression is virtually absent in most malignant salivary gland tumors, with the exception of androgen receptor expression in SDC (approximately 80 to 90 percent of tumors) and adenocarcinoma NOS [<a href="#rid26">26,55,65-67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – In salivary gland tumors with non-ACC/nonsecretory histology, with androgen receptor expression, and without HER2 overexpression, we offer chemotherapy as first-line therapy  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>). (See <a class="local">'Choice of chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leuprolide</strong><strong> acetate and </strong><strong>bicalutamide</strong> – Upon subsequent disease progression, we offer androgen deprivation therapy (ADT) with <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> acetate and <a class="drug drug_general" data-topicid="9154" href="/d/drug information/9154.html" rel="external">bicalutamide</a>. In patients with metastatic salivary gland tumors expressing androgen receptor, ADT has shown efficacy and minimal toxicity. In a single-arm, open-label phase II trial, 36 patients with salivary gland tumors (a majority of which were SDC) received combined ADT with leuprolide at 3.75 mg subcutaneously every four weeks plus bicalutamide at 80 mg daily. At a median follow-up of 15 months, ADT demonstrated an objective response rate of approximately 42 percent, median PFS of approximately nine months, and median OS of approximately 31 months [<a href="#rid66">66,68,69</a>].</p><p></p><p class="bulletIndent2">A phase II randomized clinical trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01969578&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzNnmqwgolanAVBrU0knN54BzGW6i99Wi7BegLa7yebIg%3D%3D&amp;TOPIC_ID=3382" target="_blank">NCT01969578</a>, European Organisation for Research and Treatment of Cancer [EORTC] 1206) evaluating androgen receptor blockade with <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> and <a class="drug drug_general" data-topicid="9154" href="/d/drug information/9154.html" rel="external">bicalutamide</a> versus chemotherapy (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>) is ongoing. The results will help to optimize the sequencing of ADT in androgen receptor-expressing salivary gland tumors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Enzalutamide</strong> – In a phase II trial, <a class="drug drug_general" data-topicid="86370" href="/d/drug information/86370.html" rel="external">enzalutamide</a> demonstrated some limited activity among patients with advanced unresectable and metastatic salivary gland tumors that expressed androgen receptor, including those treated with prior ADT [<a href="#rid70">70</a>]. </p><p></p><p class="headingAnchor" id="H2738890747"><span class="h4">No molecular target identified</span><span class="headingEndMark"> — </span>Patients with nonadenoid cystic tumors who lack molecular targets are treated with chemotherapy or may be offered clinical trials  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>). (See <a class="local">'Choice of chemotherapy'</a> below and <a class="local">'Investigational agents'</a> below.)</p><p class="headingAnchor" id="H2770421961"><span class="h2">Choice of chemotherapy</span><span class="headingEndMark"> — </span>For those in whom systemic therapy is warranted, chemotherapy is typically chosen as initial therapy (with the exception of those with <em>NTRK</em> fusion-positive cancers)  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>). (See <a class="local">'Secretory (NTRK gene fusion positive)'</a> above.)</p><p>For most of those eligible for systemic treatment with chemotherapy, we suggest the use of platinum and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> combination chemotherapy (such as <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, doxorubicin, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [CAP]) as first-line treatment, rather than single-agent chemotherapy, in order to maximize treatment response. However, for those with HER2-positive tumors, we typically opt for a taxane-based chemotherapy with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>. (See <a class="local">'HER2 overexpression'</a> above.)</p><p>However, for some patients, single-agent chemotherapy may be appropriate (eg, those with a borderline performance status). If single-agent therapy is used, we offer <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a> or <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>. We do not use <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> in tumors with ACC histology given the lack of efficacy.</p><p>Limited data suggest that there are differences in chemotherapy sensitivity among the histologic subtypes of salivary gland tumors. As an example, single-agent <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> appears to have activity against adenocarcinomas and mucoepidermoid carcinomas but not ACCs [<a href="#rid25">25,71</a>]. Whether there are differences with other agents or regimens is difficult to ascertain because of the small numbers of patients included in individual reports  (<a class="graphic graphic_table graphicRef81091" href="/d/graphic/81091.html" rel="external">table 2</a>). The data regarding various regimens are summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin</strong><strong>, </strong><strong>doxorubicin</strong><strong>, and </strong><strong>cyclophosphamide</strong><strong> (CAP)</strong> – The most commonly studied regimen is <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (500 mg/m<sup>2</sup> intravenously), <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (50 mg/m<sup>2</sup>), and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (50 mg/m<sup>2</sup>) administered on day 1 and repeated every 28 days [<a href="#rid72">72</a>]. Reported objective response rates are 40 to 50 percent, with duration of response ranging from three to seven months  (<a class="graphic graphic_table graphicRef81091" href="/d/graphic/81091.html" rel="external">table 2</a>) [<a href="#rid72">72-78</a>]. Combination chemotherapy regimens generally result in higher response rates but are not clearly superior in survival outcomes, despite additional toxicity. There are no trials that compare CAP versus single-agent therapy or other combination regimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of efficacy of </strong><strong>paclitaxel</strong><strong> in adenoid cystic carcinoma</strong> – A systematic review failed to find sufficient activity for <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> in the treatment of metastatic or locally recurrent ACC [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single chemotherapy agents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">Vinorelbine</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (or <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>), and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> have modest single-agent activity in treating metastatic disease, with response rates between 10 and 40 percent  (<a class="graphic graphic_table graphicRef81091" href="/d/graphic/81091.html" rel="external">table 2</a>) [<a href="#rid25">25,79-83</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In ACC, single-agent <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> has similar efficacy to <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, and <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, but it is associated with greater toxicity and should not be routinely used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other combination regimens</strong> – Other regimens evaluated in patients with advanced or recurrent disease include the following  (<a class="graphic graphic_table graphicRef81091" href="/d/graphic/81091.html" rel="external">table 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The addition of <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> to CAP had a 50 percent objective response rate in 16 evaluable patients but was associated with significant toxicity, including two treatment-related deaths (one from neutropenic sepsis and the other from doxorubicin-related cardiotoxicity) [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (or <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>), and <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (PAF) resulted in objective response rates of 35 to 40 percent in patients with metastatic disease [<a href="#rid85">85-87</a>]. Response duration was 6 to 15 months, and toxicity was tolerable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one of the only randomized trials that were conducted in patients with metastatic disease, 36 patients were randomly assigned to <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a> (25 mg/m<sup>2</sup> on days 1 and 8) plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (80 mg/m<sup>2</sup> on day 1) or to vinorelbine alone (30 mg/m<sup>2</sup> weekly) [<a href="#rid83">83</a>]. Combination therapy was associated with a significantly higher complete response rate (19 versus 0 percent), a significantly higher objective response rate (44 versus 20 percent), and a greater likelihood of survival beyond one year (38 versus 5 percent). Toxicity, in particular nausea and vomiting, was greater in the cisplatin-containing arm.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other platinum-based regimens, such as <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> [<a href="#rid88">88</a>], cisplatin plus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> [<a href="#rid9">9</a>], cisplatin plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid89">89</a>], <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid90">90,91</a>], and cisplatin plus <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> with either <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> [<a href="#rid9">9,73,92,93</a>], have demonstrated moderate activity in small trials  (<a class="graphic graphic_table graphicRef81091" href="/d/graphic/81091.html" rel="external">table 2</a>).</p><p></p><p class="headingAnchor" id="H2025746521"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H444891705"><span class="h2">MSI-H or high TMB tumors</span><span class="headingEndMark"> — </span>The immune checkpoint inhibitor (ICI) <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is an option for salivary gland tumors that are microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR), or express high levels of tumor mutational burden (TMB) and have progressed on other therapies. Further details are discussed separately. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p>For patients with salivary gland tumors that lack these molecular alterations, ICIs have shown limited activity in clinical trials, such as <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (KEYNOTE-028) [<a href="#rid94">94</a>] and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (NISCAHN) [<a href="#rid95">95</a>]. </p><p class="headingAnchor" id="H2141378418"><span class="h1">INVESTIGATIONAL AGENTS</span><span class="headingEndMark"> — </span>Patients with recurrent or metastatic salivary gland tumors should be encouraged to enroll in clinical trials, where available (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=3382" target="_blank">www.clinicaltrials.gov</a>). </p><p>Most targeted agents have not improved objective response rates in patients with salivary gland tumors. Some of these agents have stabilized disease, but this could reflect either antitumor activity or the indolent natural history of some salivary gland tumors, as many trials did not require evidence of disease progression prior to enrollment. Examples of some agents that are under investigation in salivary gland tumors include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Farnesyltransferase inhibitors</strong> – In one phase II study, the farnesyltransferase inhibitor tipifarnib demonstrated disease stabilization in approximately half of 13 patients with recurrent or metastatic <em>HRAS</em>-mutant salivary gland tumors [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer", section on 'Farnesyltransferase inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NOTCH inhibitors</strong> – In preliminary results from a phase II trial (ACCURACY) of recurrent/metastatic adenoid cystic carcinoma (ACC), the NOTCH inhibitor AL101 demonstrated an objective response rate of 12 percent and stabilized disease in over half of patients (57 percent) [<a href="#rid97">97,98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avelumab</strong><strong> plus </strong><strong>axitinib</strong> – The combination of <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> plus <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> was evaluated in a phase II trial of 40 patients with recurrent/metastatic ACC. At median follow-up of 22 months, among 28 evaluable patients, the confirmed objective response and stable disease rates were 18 and 50 percent, respectively. Median progression-free survival (PFS) and overall survival (OS) were 7 and 17 months, respectively [<a href="#rid99">99</a>]. </p><p></p><p class="headingAnchor" id="H247552273"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomy</strong> – Salivary glands produce and secrete saliva from a glandular structure that includes the secretory acinus, the ducts, and the myoepithelial and basal cells. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Salivary gland tumors can be benign or malignant  (<a class="graphic graphic_table graphicRef116708" href="/d/graphic/116708.html" rel="external">table 1</a>) and can arise from either the major (parotid, submandibular, and sublingual) or minor salivary glands located in the oral cavity, paranasal sinuses, larynx, and pharynx  (<a class="graphic graphic_figure graphicRef115303" href="/d/graphic/115303.html" rel="external">figure 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Locoregionally recurrent disease</strong> – For patients with locoregionally recurrent disease, surgical salvage is the optimal treatment if the disease is resectable. (See <a class="local">'Locoregionally recurrent disease'</a> above.)</p><p></p><p class="bulletIndent1">For patients who undergo salvage surgery and who have not received radiation therapy (RT) as part of treatment for their original disease presentation, we suggest adjuvant RT rather than observation alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Local relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment indications (metastatic disease) </strong>– In patients with metastatic disease, treatment indications are as follows (see <a class="local">'Indications for treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have one single site affecting a critical structure but have otherwise stable systemic disease, or for those with oligometastatic disease, we suggest locoregional therapies, with or without systemic therapy, rather than systemic therapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with solitary metastases, particularly in the lungs or liver and of adenoid cystic carcinoma (ACC) histology, may be most likely to benefit from this approach. (See <a class="local">'Local treatments'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic therapy  (<a class="graphic graphic_algorithm graphicRef122232" href="/d/graphic/122232.html" rel="external">algorithm 1</a>) is offered to patients with an increasing rate of systemic disease progression based on imaging, with systemic symptoms, with threatened end-organ dysfunction, and/or with a declined performance status due to progressive disease. (See <a class="local">'Systemic treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By contrast, for patients with indolent, asymptomatic, or minimally symptomatic disease, regardless of histologic subtype, we offer surveillance. (See <a class="local">'Surveillance for those without treatment indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salivary gland tumors of any histology with rare driver mutations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>RET</em></strong><strong> fusion-positive tumors</strong> – For patients with rearranged during transfection (<em>RET)</em> fusion-positive salivary gland tumor of any histology and no other actionable mutations, we suggest initial therapy with <a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">selpercatinib</a> rather than chemotherapy or other systemic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'RET fusion-positive tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>BRAF</em></strong><strong> V600E mutation-positive tumors</strong> – For patients with a metastatic salivary gland tumor of any histology that harbors a <em>BRAF</em> V600E mutation and no other actionable molecular alterations, we suggest initial therapy with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> rather than chemotherapy or other systemic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'BRAF V600E mutant tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACC or non-ACC histology lacking a driver mutation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For most patients with indications for systemic treatment, either ACC <strong>or </strong>non-ACC histology, and whose tumor lacks a molecular driver mutation, we suggest a combination chemotherapy regimen as initial treatment (eg, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [CAP]), rather than single-agent therapy, to maximize treatment response (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, for some patients who may not be able to tolerate chemotherapy combinations, a single agent may be an appropriate alternative. If single-agent therapy is used, we offer <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a> or <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>. For those with ACC histology, we avoid taxanes in the chemotherapy regimen, due to lack of efficacy. (See <a class="local">'Adenoid cystic carcinoma'</a> above and <a class="local">'Choice of chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent therapy</strong> – For patients with ACC tumors lacking a driver mutation who progress on initial therapy and remain candidates for treatment, we offer subsequent therapy with the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>. <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> and <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> are alternative options that also target VEGF inhibition. (See <a class="local">'Adenoid cystic carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-ACC histology</strong> – For patients with non-ACC histology and indications for treatment, we obtain testing for specific molecular targets based on histology to help determine choice of systemic therapy. (See <a class="local">'Molecular testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secretory tumors</strong> – For non-ACC secretory tumors (ie, mammary analogue secretory carcinoma), we obtain testing for a neurotrophic tyrosine receptor kinase (<em>NTRK</em>) gene fusion  (<a class="graphic graphic_algorithm graphicRef126093" href="/d/graphic/126093.html" rel="external">algorithm 2</a>). For those who test positive for an <em>NTRK</em> gene fusion without a known acquired resistance mutation, we suggest targeted therapy with <a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a> rather than cytotoxic chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Secretory (NTRK gene fusion positive)'</a> above and  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsecretory tumors</strong> – For non-ACC nonsecretory tumors (eg, mucoepidermoid carcinoma, salivary ductal carcinoma, and adenocarcinoma not otherwise specified), we obtain testing for androgen receptor and human epidermal growth factor receptor 2 (HER2) expression.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>HER2 positive</strong> – For patients with overexpression of HER2, we suggest the addition of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> to taxane-based chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Trastuzumab plus <a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">pertuzumab</a> is an appropriate alternative for patients with HER2-positive salivary gland tumors who wish to avoid the potential toxicities of chemotherapy or have a contraindication to taxanes.</p><p></p><p class="bulletIndent3">For patients progressing on HER2-directed therapy, options for subsequent therapy include <a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a> (T-DM1) and <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a>. (See <a class="local">'HER2 overexpression'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Androgen receptor positive, HER2 negative</strong> – For patients with androgen receptor expression and without HER2 overexpression, we suggest chemotherapy as initial treatment rather than androgen deprivation therapy (ADT) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, we opt for ADT with <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> plus <a class="drug drug_general" data-topicid="9154" href="/d/drug information/9154.html" rel="external">bicalutamide</a> upon disease progression. <a class="drug drug_general" data-topicid="86370" href="/d/drug information/86370.html" rel="external">Enzalutamide</a> also has some limited activity as subsequent therapy. (See <a class="local">'Androgen receptor positive'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dai D. Postoperative irradiation in malignant tumors of submandibular gland. Cancer Invest 1999; 17:36.</a></li><li><a class="nounderline abstract_t">Mücke T, Tannapfel A, Kesting MR, et al. Adenoid cystic carcinomas of minor salivary glands. Auris Nasus Larynx 2010; 37:615.</a></li><li><a class="nounderline abstract_t">Laramore GE. Role of particle radiotherapy in the management of head and neck cancer. Curr Opin Oncol 2009; 21:224.</a></li><li><a class="nounderline abstract_t">Chen AM, Garcia J, Bucci MK, et al. Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy. Head Neck 2008; 30:2.</a></li><li><a class="nounderline abstract_t">Haddad RI, Posner MR, Busse PM, et al. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol 2006; 29:153.</a></li><li><a class="nounderline abstract_t">Barnett TA, Kapp DS, Goffinet DR. Adenoid cystic carcinoma of the salivary glands. Management of recurrent, advanced, or persistent disease with hyperthermia and radiation therapy. Cancer 1990; 65:2648.</a></li><li><a class="nounderline abstract_t">Gabriele P, Amichetti M, Orecchia R, Valdagni R. Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. Cancer 1995; 75:908.</a></li><li><a class="nounderline abstract_t">Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol 2010; 95:308.</a></li><li><a class="nounderline abstract_t">Hill ME, Constenla DO, A'Hern RP, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997; 33:275.</a></li><li><a class="nounderline abstract_t">Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 1997; 174:495.</a></li><li><a class="nounderline abstract_t">Sung MW, Kim KH, Kim JW, et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2003; 129:1193.</a></li><li><a class="nounderline abstract_t">van der Wal JE, Becking AG, Snow GB, van der Waal I. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck 2002; 24:779.</a></li><li><a class="nounderline abstract_t">Sur RK, Donde B, Levin V, et al. Adenoid cystic carcinoma of the salivary glands: a review of 10 years. Laryngoscope 1997; 107:1276.</a></li><li><a class="nounderline abstract_t">Yu T, Gao QH, Wang XY, et al. Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases. Oncology 2007; 72:39.</a></li><li><a class="nounderline abstract_t">Fang Q, Wu J, Du W, Zhang X. Predictors of distant metastasis in parotid acinic cell carcinoma. BMC Cancer 2019; 19:475.</a></li><li><a class="nounderline abstract_t">Su YX, Roberts DB, Hanna EY, et al. Risk Factors and Prognosis for Myoepithelial Carcinoma of the Major Salivary Glands. Ann Surg Oncol 2015; 22:3701.</a></li><li><a class="nounderline abstract_t">Shenoy N. Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy. Cancer 2020; 126:5198.</a></li><li><a class="nounderline abstract_t">Locati LD, Guzzo M, Bossi P, et al. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol 2005; 41:890.</a></li><li><a class="nounderline abstract_t">Qureshi SS, Nadkarni MS, Shrikhande SV, et al. Hepatic resection for metastasis from adenoid cystic carcinoma of parotid gland. Indian J Gastroenterol 2005; 24:29.</a></li><li><a class="nounderline abstract_t">Gruttadauria S, Marino G, Catalano F, et al. Secondary carcinoma of the liver from parotid gland tumor. Chir Ital 2000; 52:179.</a></li><li><a class="nounderline abstract_t">Ishihama H, Kobayashi S, Ikeda Y, et al. [Surgical treatment for pulmonary metastasis from submandibular gland cancer]. Kyobu Geka 2003; 56:51.</a></li><li><a class="nounderline abstract_t">Sidhu GS, Forrester EM. Acinic cell carcinoma: long-term survival after pulmonary metastases: light and electron microscopic study. Cancer 1977; 40:756.</a></li><li><a class="nounderline abstract_t">Liu D, Labow DM, Dang N, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol 1999; 6:572.</a></li><li><a class="nounderline abstract_t">Mimica X, McGill M, Hay A, et al. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer 2020; 126:2153.</a></li><li><a class="nounderline abstract_t">Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011; 12:815.</a></li><li><a class="nounderline abstract_t">Even C, Baste N, Classe M. New approaches in salivary gland carcinoma. Curr Opin Oncol 2019; 31:169.</a></li><li><a class="nounderline abstract_t">Schvartsman G, Pinto NA, Bell D, Ferrarotto R. Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease. Head Neck 2019; 41:239.</a></li><li><a class="nounderline abstract_t">Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022; 23:1261.</a></li><li class="breakAll">Selpercatinib: US Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf (Accessed on October 13, 2022).</li><li class="breakAll">United States (US) Food and Drug Administration (FDA) Prescribing Label for Dabrafenib https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s027lbl.pdf (Accessed on September 06, 2023).</li><li class="breakAll">United States (US) Food and Drug Administration (FDA) Prescribing Label for trametinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf (Accessed on June 26, 2023).</li><li><a class="nounderline abstract_t">Lin VTG, Nabell LM, Spencer SA, et al. First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition. J Natl Compr Canc Netw 2018; 16:1166.</a></li><li><a class="nounderline abstract_t">Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. J Clin Oncol 2019; 37:1529.</a></li><li><a class="nounderline abstract_t">Locati LD, Galbiati D, Calareso G, et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer 2020; 126:1888.</a></li><li><a class="nounderline abstract_t">Locati LD, Perrone F, Cortelazzi B, et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. Eur J Cancer 2016; 69:158.</a></li><li><a class="nounderline abstract_t">Thomson DJ, Silva P, Denton K, et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck 2015; 37:182.</a></li><li><a class="nounderline abstract_t">Ho AL, Dunn L, Sherman EJ, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol 2016; 27:1902.</a></li><li><a class="nounderline abstract_t">Solomon JP, Hechtman JF. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res 2019; 79:3163.</a></li><li><a class="nounderline abstract_t">Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 2019; 30:1417.</a></li><li><a class="nounderline abstract_t">Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010; 34:599.</a></li><li><a class="nounderline abstract_t">Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731.</a></li><li class="breakAll">US Food and Drug Administration (FDA) Label for Larotrectinib https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf?et_cid=40674858&amp;et_rid=931330620&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f211710s000lbl.pdf (Accessed on November 27, 2018).</li><li><a class="nounderline abstract_t">Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:271.</a></li><li><a class="nounderline abstract_t">Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21:531.</a></li><li class="breakAll">US Food and Drug Administration (FDA) Label for Entrectinib https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf (Accessed on August 20, 2019).</li><li><a class="nounderline abstract_t">Corrêa TS, Matos GDR, Segura M, Dos Anjos CH. Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab. Case Rep Oncol 2018; 11:252.</a></li><li><a class="nounderline abstract_t">Weed DT, Gomez-Fernandez C, Pacheco J, et al. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck 2004; 26:353.</a></li><li><a class="nounderline abstract_t">Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004; 10:944.</a></li><li><a class="nounderline abstract_t">Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005; 103:2526.</a></li><li><a class="nounderline abstract_t">Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994; 54:5675.</a></li><li><a class="nounderline abstract_t">Nabili V, Tan JW, Bhuta S, et al. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007; 29:907.</a></li><li><a class="nounderline abstract_t">Dori S, Vered M, David R, Buchner A. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 2002; 31:463.</a></li><li><a class="nounderline abstract_t">Li, TB, Shen R, et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. J Clin Oncol 2019; 37S.</a></li><li><a class="nounderline abstract_t">Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003; 39:724.</a></li><li><a class="nounderline abstract_t">Takahashi H, Tada Y, Saotome T, et al. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. J Clin Oncol 2019; 37:125.</a></li><li><a class="nounderline abstract_t">Prat A, Parera M, Reyes V, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 2008; 30:680.</a></li><li><a class="nounderline abstract_t">Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol 2009; 123:250.</a></li><li><a class="nounderline abstract_t">Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 2012; 29:704.</a></li><li><a class="nounderline abstract_t">Limaye SA, Posner MR, Krane JF, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 2013; 18:294.</a></li><li><a class="nounderline abstract_t">Thorpe LM, Schrock AB, Erlich RL, et al. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. Head Neck 2017; 39:E40.</a></li><li><a class="nounderline abstract_t">Lee J, Park S, Jung HA, et al. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. Cancer 2023; 129:2966.</a></li><li><a class="nounderline abstract_t">Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 2020; 31:412.</a></li><li><a class="nounderline abstract_t">Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 2019; 30:1821.</a></li><li><a class="nounderline abstract_t">Bando H, Kinoshita I, Modi S, et al. Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies. J Clin Oncol 39;15S.</a></li><li><a class="nounderline abstract_t">Fan CY, Melhem MF, Hosal AS, et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001; 127:1075.</a></li><li><a class="nounderline abstract_t">Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 2018; 29:979.</a></li><li><a class="nounderline abstract_t">Szewczyk M, Marszałek A, Sygut J, et al. Prognostic markers in salivary gland cancer and their impact on survival. Head Neck 2019; 41:3338.</a></li><li><a class="nounderline abstract_t">Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck 2018; 40:605.</a></li><li><a class="nounderline abstract_t">van Boxtel W, Locati LD, van Engen-van Grunsven ACH, et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur J Cancer 2019; 110:62.</a></li><li><a class="nounderline abstract_t">Ho AL, Foster NR, Zoroufy AJ, et al. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). J Clin Oncol 2022; 40:4240.</a></li><li><a class="nounderline abstract_t">Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006; 28:197.</a></li><li><a class="nounderline abstract_t">Dreyfuss AI, Clark JR, Fallon BG, et al. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 1987; 60:2869.</a></li><li><a class="nounderline abstract_t">Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986; 95:165.</a></li><li><a class="nounderline abstract_t">Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996; 7:640.</a></li><li><a class="nounderline abstract_t">Creagan ET, Woods JE, Rubin J, Schaid DJ. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 1988; 62:2313.</a></li><li><a class="nounderline abstract_t">Alberts DS, Manning MR, Coulthard SW, et al. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 1981; 47:645.</a></li><li><a class="nounderline abstract_t">Belani CP, Eisenberger MA, Gray WC. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol 1988; 16:197.</a></li><li><a class="nounderline abstract_t">Tsukuda M, Kokatsu T, Ito K, et al. Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck. J Cancer Res Clin Oncol 1993; 119:756.</a></li><li><a class="nounderline abstract_t">Licitra L, Marchini S, Spinazzè S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991; 68:1874.</a></li><li><a class="nounderline abstract_t">Schramm VL Jr, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 1981; 107:739.</a></li><li><a class="nounderline abstract_t">Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1996; 7:867.</a></li><li><a class="nounderline abstract_t">Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993; 4:785.</a></li><li><a class="nounderline abstract_t">Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001; 91:541.</a></li><li><a class="nounderline abstract_t">Dimery IW, Legha SS, Shirinian M, Hong WK. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990; 8:1056.</a></li><li><a class="nounderline abstract_t">Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987; 5:951.</a></li><li><a class="nounderline abstract_t">Airoldi M, Pedani F, Brando V, et al. Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori 1989; 75:252.</a></li><li><a class="nounderline abstract_t">Farhat F, Kattan J, Culine S, et al. [Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature]. Bull Cancer 1994; 81:47.</a></li><li><a class="nounderline abstract_t">Gedlicka C, Schüll B, Formanek M, et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs 2002; 13:491.</a></li><li><a class="nounderline abstract_t">Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 2010; 116:362.</a></li><li><a class="nounderline abstract_t">Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 2000; 20:3781.</a></li><li><a class="nounderline abstract_t">Ruzich JC, Ciesla MC, Clark JI. Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Head Neck 2002; 24:406.</a></li><li><a class="nounderline abstract_t">Posner MR, Ervin TJ, Weichselbaum RR, et al. Chemotherapy of advanced salivary gland neoplasms. Cancer 1982; 50:2261.</a></li><li><a class="nounderline abstract_t">de Haan LD, De Mulder PH, Vermorken JB, et al. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 1992; 14:273.</a></li><li><a class="nounderline abstract_t">Cohen RB, Delord JP, Doi T, et al. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol 2018; 41:1083.</a></li><li><a class="nounderline abstract_t">Fayette J, Even C, Digue L, et al. NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head &amp; Neck Group. J Clin Oncol 2019; 37;15S.</a></li><li><a class="nounderline abstract_t">Hanna GJ, Guenette JP, Chau NG, et al. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer 2020; 126:3972.</a></li><li><a class="nounderline abstract_t">Ferrarotto R, Metcalf R, Rodriguez CP, et al. Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). J Clin Oncol 40; 16S.</a></li><li><a class="nounderline abstract_t">Ferrarotto R, Mishra V, Herz E, et al. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis 2022; 13:678.</a></li><li><a class="nounderline abstract_t">Ferrarotto R, Sousa LG, Feng L, et al. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol 2023; 41:2843.</a></li></ol></div><div id="topicVersionRevision">Topic 3382 Version 64.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999047" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Postoperative irradiation in malignant tumors of submandibular gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181451" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adenoid cystic carcinomas of minor salivary glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370806" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Role of particle radiotherapy in the management of head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17828788" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601434" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2160315" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adenoid cystic carcinoma of the salivary glands. Management of recurrent, advanced, or persistent disease with hyperthermia and radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842410" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385414" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chemoreirradiation for recurrent salivary gland malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307718" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9374223" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Distant metastasis in adenoid cystic carcinoma of salivary origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14623749" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12203804" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292617" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adenoid cystic carcinoma of the salivary glands: a review of 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17998789" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31113416" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Predictors of distant metastasis in parotid acinic cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636455" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk Factors and Prognosis for Myoepithelial Carcinoma of the Major Salivary Glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33048366" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043380" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778528" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hepatic resection for metastasis from adenoid cystic carcinoma of parotid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10832544" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Secondary carcinoma of the liver from parotid gland tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12607254" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Surgical treatment for pulmonary metastasis from submandibular gland cancer].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/890656" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acinic cell carcinoma: long-term survival after pulmonary metastases: light and electron microscopic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10493626" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulmonary metastasectomy for head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097509" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Distant metastasis of salivary gland cancer: Incidence, management, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147032" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30844885" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : New approaches in salivary gland carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30552848" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30323086" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30939095" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031693" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821319" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24346857" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27566443" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31196931" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31268127" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410810" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838007" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32105622" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32105622" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29867432" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15054739" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871971" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : HER2 expression in salivary gland carcinomas: dependence on histological subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900577" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7522962" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563907" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220353" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12907212" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30452336" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17972317" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18405406" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Biological therapy of salivary duct carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21380780" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429737" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Trastuzumab for the treatment of salivary duct carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28006087" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37246414" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32067683" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504139" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556855" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29211833" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246357" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prognostic markers in salivary gland cancer and their impact on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29272069" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30771738" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35867947" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470745" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2824016" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3035459" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chemotherapy for salivary gland cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879381" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3179947" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7194729" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2837623" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Preliminary experience with chemotherapy in advanced salivary gland neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408188" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913539" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6274284" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cisplatin therapy for adenoid cystic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922205" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8280659" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11169936" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2112183" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3585449" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475951" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7949584" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : [Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045460" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924794" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11268454" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Paclitaxel and carboplatin for recurrent salivary gland malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11933184" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6754060" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Chemotherapy of advanced salivary gland neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381339" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29462123" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head&amp;Neck Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32557577" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35931701" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36898078" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
